The global sarcopenia treatment market is forecast to grow at a compound annual growth rate (CAGR) of more than 6% during the forecast period from 2021-2030, and the market value anticipates to reach USD 4700 million by 2030. 

A condition known as sarcopenia occurs when skeletal muscle mass or flesh decreases with aging. Reduced muscle mass, relative weakness, a lack of stamina, and problems climbing stairs are some of the symptoms of sarcopenia. In addition, to exercise level and co-morbidities, there are other factors affecting muscle loss. Sarcopenia can impair quality of life and lead to disability. The aging process causes muscles to lose strength and muscle mass. 

Malnutrition is a result of low consumption of micronutrient-rich foods in developing and low-income countries. It results from malnutrition or vitamin D and vitamin B12 deficiency. Vegetarians and the elderly are more at risk for this condition. Therefore, sarcopenia has no recognized treatment; however, proper nutrition and dietary supplements can help. During periods of muscle inactivity, diet prevents accelerated muscle loss and keeps energy levels up. A few of the most effective supplements for treating sarcopenia are proteins, amino acids, omega-3 fatty acids, creatine, vitamin D, and vitamin B12. 

Factors Affecting

• Factors driving the global sarcopenia treatment market include an aging population and the increasing acceptance of vitamins and dietary supplements. The World Health Organization predicts that by 2050, there will be 2 billion people aged 60 and older in the world, up from 900 million in 2015. Furthermore, a rise in sarcopenia cases will drive the growth of treatment products for the condition.
• Sarcopenia treatment market growth will also benefit from an increase in R&D activities.
• During the forecast period, high protein supplement prices and a lack of awareness will hinder the market growth.
• As malnutrition and vitamin deficiency rise in developing countries and healthcare spending rises per capita, sarcopenia treatment supplements will likely become more in demand. 
• The increase in malnutrition cases resulting from poor nutrition will provide additional growth opportunities for the sarcopenia treatment market during the forecast period.
• Despite these obstacles, protein supplement prices could increase, and sarcopenia treatment drugs will become more difficult to acquire.

Impact Analysis of COVID-19

The COVID-19 study may boost sarcopenia treatment market growth. COVID-19 infection causes a systematic inflammation that leads to skeletal muscle death in patients with sarcopenia. In addition, older people who suffered social isolation during the COVID-19 pandemic suffered protein deficiencies and reduced physical activity, which lead to accelerated muscle weakness and dysfunction. Those with COVID-19 are also likely to experience secondary sarcopenia for two or three weeks after diagnosis. The result was an increase in the demand for protein supplements that promote muscle growth and increase muscle strength. A secondary recommendation should be to have physically isolated individuals do daily exercises such as ViviFrail graded exercise, the primary treatment for sarcopenia. COVID-19 has therefore grown positively as a result of such factors.

Regional Overview

The Asia-Pacific region accounted for the largest share, continuing to retain its dominance through 2030 due to high R&D spending, the presence of leading players and their products, and well-established healthcare infrastructure. 

Prominent Players

The prominent players profiled in the global sarcopenia treatment market are:

• Abbott Laboratories, Inc. (U.S.)
• American Way (Amway) Corporation (U.S.)
• Bayer AG (Germany)
• GlaxoSmithKline plc. (U.K.)
• Nestle S.A. (Europe) 
• Pfizer, Inc. (U.S.)
• Novartis AG (Europe)
• Sanofi, Inc. (France)
• Zydus Cadila, Ltd (India)
• F-Hoffmann La-Roche (Europe)
• Other Prominent Players

Scope of the Report

The global sarcopenia market segmentation focuses on Treatment, Route of Administration, Distribution Channel, and Region.

Segmentation based on Treatment

• Protein Supplements
• Vitamin B12 Supplements
• Vitamin D & Calcium Supplements
• Others 

Segmentation based on Route of Administration

• Oral
  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies
• Parenteral
  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies
• Enteral
  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

Segmentation based on Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

Segmentation based on Region 

• North America
• The U.S.
• Canada
• Mexico
• Europe
• Western Europe
• The UK
• Germany
• France
• Italy
• Spain
• Rest of Western Europe
• Eastern Europe
• Poland
• Russia
• Rest of Eastern Europe
• Asia Pacific
• China
• India
• Japan
• Australia & New Zealand
• ASEAN
• Rest of Asia Pacific
• Middle East & Africa (MEA)
• UAE
• Saudi Arabia
• South Africa
• Rest of MEA
• South America
• Brazil
• Argentina
• Rest of South America